Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue , 2015, Pages 35-44

  Park, Sang Hyoung ^a   Kim, Young Ho ^b   Lee, Ji Hyun ^c   Kwon, Hyeok Jin ^c   Lee, Suck Ho ^d   Park, Dong Il ^e   Kim, Hyung Kil ^f   Cheon, Jae Hee ^g   Im, Jong Pil ^h   Kim, You Sun ⁱ   Lee, Sung Young ^j   Lee, Sang Joon ^j  

^a University of Ulsan   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Seoul Song Do Colorectal Hospital   (South Korea)

^d Esoo Hospital   (South Korea)

^e School of Medicine   (South Korea)

^f Inha University School of Medicine   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h Seoul National University   (South Korea)

ⁱ Inje University College of Medicine   (South Korea)

^j Celltrion Inc   (South Korea)

more..

Author keywords

biosimilar; Crohn's disease; CT P13; efficacy; inflammatory bowel disease; infliximab; post marketing study; safety; South Korea; switching; ulcerative colitis

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; STEROID; ANTIINFLAMMATORY AGENT; BIOSIMILAR AGENT; CT-P13; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; AGED; ANAPHYLAXIS; ARTICLE; CROHN DISEASE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; HYPERSENSITIVITY; HYPESTHESIA; INFECTION; INFUSION RELATED REACTION; LEUKOPENIA; LUNG ABSCESS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOPLASM; NEUTROPENIA; PHASE 4 CLINICAL TRIAL; PHOTOSENSITIVITY; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRURITUS; RASH; REMISSION; RHINITIS; SKIN DEFECT; SOUTH KOREA; THORAX PAIN; TREATMENT OUTCOME; TUBERCULOSIS; ULCERATIVE COLITIS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLITIS, ULCERATIVE; IMMUNOLOGY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; REMISSION INDUCTION; REPUBLIC OF KOREA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84942325078     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1091309     Document Type: Article

References (44)

1. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012; 6: 965-90
2. Fakhoury M, Negrulj R, Mooranian A, et al. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res 2014; 7: 113-20
3. Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohns disease. World J Gastroenterol 2012; 18: 4823-54
4. Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol 2015; 8: 66-82
5. Kotze PG, Saad-Hossne R. Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohns disease: time for acceptance? Intest Res 2015; 11: 256-60
6. Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007; 83: 251-60
7. Ye BD. Could early anti-tumor necrosis factor therapy change the prognosis of Crohns disease? Intest Res 2014; 12: 263-5
8. De Cruz P, Kamm MA, Hamilton AL, et al. Crohns disease management after intestinal resection: a randomised trial. Lancet 2015; 385: 1406-17
9. European Medicines Agency. Remicade (infliximab). Summary of product characteristics. 2009. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000240/WC500050888.pdf. [Last accessed 3 August 2015]
10. Kopylov U, Ben-Horin S, Seidman E. Therapeutic drug monitoring in inflammatory bowel disease. Ann Gastroenterol 2014; 27: 304-12
11. European Medicines Agency. Remsima (infliximab). Summary of product characteristics. 2014. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002576/WC500150871.pdf. [Last accessed 3 August 2015]
12. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Remsima (infliximab). 2013. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002576/WC500151486.pdf. [Last accessed 3 August 2015]
13. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72: 1605-12
14. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72: 1613-20
15. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. Available from: www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/01/WC500180219.pdf. [Last accessed 3 August 2015]
16. Fiorino G, Danese S. The biosimilar road in inflammatory bowel disease: the right way? Best Pract Res Clin Gastroenterol 2014; 28: 465-71
17. Generics and Biosimilars Initiative. Biosimilars approved in South Korea. 2014. Available from: http://gabionline.net/Biosimilars/General/Biosimilars-Approved-in-South-Korea. [Last accessed 3 August 2015]
18. Generics and Biosimilars Initiative. Biosimilars approved in Japan 2014. Available from: http://gabionline.net/Biosimilars/General/Biosimilars-Approved-in-Japan. [Last accessed 3 August 2015]
19. Health Canada. Summary Basis of Decision (SBD) for Remsima. 2014. Available from: www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2014-remsima-160195-eng.php#sbd. [Last accessed 3 August 2015]
20. Griffin MR, Stein CM, Ray WA. Postmarketing surveillance for drug safety: surely we can do better. Clin Pharmacol Ther 2004; 75: 491-4
21. Lahiff C, Kane S, Moss AC. Drug development in inflammatory bowel disease: the role of the FDA. Inflamm Bowel Dis 2011; 17: 2585-93
22. Smolen JS, Emery P. Infliximab: 12 years of experience. Arthritis Res Ther 2011; 13 (Suppl 1): S2
23. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 189-94
24. Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol 2015. [Epub ahead of print]
25. Orlando A, Armuzzi A, Papi C, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-Alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011; 43: 1-20
26. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-Aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9
27. Medical Dictionary for Regulatory Activities. Available from: www.meddra.org/. [Last accessed 3 August 2015]
28. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohns disease. Gastroenterology 2004; 126: 402-13
29. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med 2004; 350: 876-85
30. Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohns disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2: 912-20
31. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-7
32. Sandborn WJ, Colombel JF, DHaens G, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-13
33. Sakuraba A, Sato T, Matsukawa H, et al. The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohns disease patients: a pilot open-labeled prospective study. Int J Colorectal Dis 2012; 27: 947-52
34. Yoshida K, Fukunaga K, Ikeuchi H, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohns disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis 2012; 18: 1617-23
35. Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012; 18: 201-11
36. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohns disease. Gut 2007; 56: 1226-31
37. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohns disease: a prospective cohort study. Gastroenterology 2003; 125: 32-9
38. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohns disease. Am J Gastroenterol 2000; 95: 3490-7
39. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohns disease. N Engl J Med 2010; 362: 1383-95
40. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9
41. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76
42. Demonstrate noninferiority in efficacy and to assess safety of CT-P13 in patients with active Crohns disease. Available from: https://clinicaltrials.gov/ct2/show/NCT02096861
43. To evaluate the safety and efficacy of Remsima™ in patients with Crohns disease (CD) or ulcerative colitis (UC). Available from: https://clinicaltrials.gov/ct2/show/NCT02326155
44. The NOR-SWITCH Study. Available from: https://clinicaltrials.gov/ct2/show/NCT02148640